buyWeak

Redmile Group, LLC bought $609k of ADCT

owner at ADC Therapeutics SA. 200,000 shares at an average of $3.05, traded Dec 11, 2024, filed Dec 13, 2024.

Conviction score

Value

$609k

200,000 shares

Holdings after

13,145,712

+1% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
10% owner
+12
Trade size
$609k at market
+20
Relative to holdings
Holdings up 1.3%
0
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0
Outside holder
A 10% owner who is not an officer or director
-5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ADCTOct 9, 2026 · close 1.73

Since filing Dec 13, 2024: -8.5%SPY +31.8% · excess -40.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-24-128575, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Dec 11, 2024	POpen-market purchase Common Shares, par value CHF 0.08 per shareindirect: See Footnotes	+50,000	$2.28	$114k	15,616,731	Dec 13, 2024
Dec 11, 2024	POpen-market purchase Common Shares, par value CHF 0.08 per shareindirect: See Footnotes	+50,000	$3.81	$191k	15,666,731	Dec 13, 2024
Dec 11, 2024	POpen-market purchase Common Shares, par value CHF 0.08 per share	+50,000	$2.28	$114k	13,095,712	Dec 13, 2024
Dec 11, 2024	POpen-market purchase Common Shares, par value CHF 0.08 per share	+50,000	$3.81	$191k	13,145,712	Dec 13, 2024

Related signals

Other insiders at ADC Therapeutics SA and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
19Weak	ADCTsell ADC Therapeutics SA	Redmile Group, LLC owner	$52k 25,352 shares	-0%	Dec 6, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.